Summary & Overview
CPT 0390U: Preeclampsia Risk Score from Serum Immunoassay (PEPredictDx)
CPT code 0390U designates a Proprietary Laboratory Analyses (PLA) test — PEPredictDx, OncoOmicsDx Laboratory from mProbe — that measures three serum biomarkers by immunoassay and reports a risk score for preeclampsia as early as 11 weeks of pregnancy. As a PLA code, 0390U applies to a single manufacturer-specific laboratory test and is used to identify and track utilization and payment for this proprietary assay at the national level. The code matters for payers and providers because it informs coverage policy, claims processing, and the emergence of biomarker-based prenatal risk assessment.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service settings, and the implications of using a PLA-designated CPT code. The publication summarizes payer coverage considerations, common modifiers reported with laboratory services, and the national policy context for proprietary prenatal diagnostics. It also outlines what stakeholders should expect in terms of billing and documentation practices and highlights areas where data are not available in the input. This national-focused summary provides clinicians, billing professionals, and policy analysts with a clear, high-level brief on 0390U and its role in prenatal care pathways.
Billing Code Overview
CPT code 0390U is a Proprietary Laboratory Analyses (PLA) code reported only for the PEPredictDx, OncoOmicsDx Laboratory from mProbe. The test evaluates a patient blood (serum) specimen for three biomarkers using an immunoassay technique and reports a risk score for preeclampsia (PE) as early as 11 weeks of pregnancy.
-
Service type: Proprietary laboratory diagnostic blood test (serum immunoassay) that produces a risk score for preeclampsia.
-
Typical site of service: Clinical laboratory or reference laboratory processing serum specimens collected from pregnant patients.
Clinical & Coding Specifications
Clinical Context
A pregnant patient presenting for routine prenatal care at 11–20 weeks gestation undergoes screening for preeclampsia risk. A maternal-fetal medicine specialist or obstetrician orders the proprietary PEPredictDx assay (0390U) performed by OncoOmicsDx Laboratory from mProbe. A blood (serum) specimen is collected in an outpatient clinic or laboratory draw station (typical site of service: outpatient laboratory or ambulatory clinic). The specimen is sent to the reference laboratory where an immunoassay measures three biomarkers and the laboratory reports a validated risk score for preeclampsia to the ordering clinician. Results are used to stratify risk, guide surveillance frequency, and inform counseling during subsequent prenatal visits. Typical clinical workflow: provider orders test in electronic medical record, patient has phlebotomy encounter, specimen is shipped to the reference lab, lab performs the proprietary assay, and a report with a risk score is returned to the clinician and placed in the chart.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard use when no additional modifier applies to the service |
26 |